{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Zhou L"],"pubmed_abstract":["<h4>Background</h4>Transmural healing (TH) is a potential therapeutic goal of Crohn's disease (CD) and is associated with better clinical outcomes. However, few studies have described early TH and its predictors.<h4>Objectives</h4>We aimed to evaluate early TH and its predictors using magnetic resonance enterography (MRE) in patients with CD receiving ustekinumab (UST).<h4>Design</h4>This was a retrospective observational study.<h4>Methods</h4>Patients with active CD treated with UST and their intestinal segments with bowel wall thickness (BWT) ⩽ 3 mm at baseline were included. Clinical characteristics, laboratory indicators, endoscopic manifestations, and MRE indices were evaluated at baseline and week 26 (W26) of the therapy. The following MRE parameters were assessed: BWT, edema, appare"],"journal":["Therapeutic advances in gastroenterology"],"pagination":["17562848231170947"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10164861"],"repository":["biostudies-literature"],"pubmed_title":["Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn's disease receiving ustekinumab."],"pmcid":["PMC10164861"],"pubmed_authors":["Qiu Y","Zhou L","Li X","Hu C","Liu Z","He Y","Chen M","Mao R","Zeng Z","Wang Y","Zhang R","Chen B"],"additional_accession":[]},"is_claimable":false,"name":"Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn's disease receiving ustekinumab.","description":"<h4>Background</h4>Transmural healing (TH) is a potential therapeutic goal of Crohn's disease (CD) and is associated with better clinical outcomes. However, few studies have described early TH and its predictors.<h4>Objectives</h4>We aimed to evaluate early TH and its predictors using magnetic resonance enterography (MRE) in patients with CD receiving ustekinumab (UST).<h4>Design</h4>This was a retrospective observational study.<h4>Methods</h4>Patients with active CD treated with UST and their intestinal segments with bowel wall thickness (BWT) ⩽ 3 mm at baseline were included. Clinical characteristics, laboratory indicators, endoscopic manifestations, and MRE indices were evaluated at baseline and week 26 (W26) of the therapy. The following MRE parameters were assessed: BWT, edema, appare","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-26T17:20:35.679Z","creation":"2025-04-06T15:31:49.711Z"},"accession":"S-EPMC10164861","cross_references":{"pubmed":["37168404"],"doi":["10.1177/17562848231170947"]}}